MedTrace Logo

Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis

NCT05647096 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2024-11-29

No results posted yet for this study

Summary

This is a prospective, multinational, multicentre, randomised, parallel-group, open-label study to assess the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in the reduction of circulating cell-free DNA (cfDNA)/Neutrophil Extracellular Traps (NETs) in sepsis patients.

Conditions

Interventions

DEVICE

NucleoCapture device

100ml NucleoCapture selective DNA adsorber

Sponsors & Collaborators

  • ISS AG

    collaborator UNKNOWN

  • Santersus AG

    lead INDUSTRY

Principal Investigators

  • Andrew Aswani · Santersus AG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2027-05-05
Completion
2027-05-28

Countries

  • Germany
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05647096 on ClinicalTrials.gov